[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566200":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":62,"collaborators":32,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":32,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":51,"whyStopped":32,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"I.M. Sechenov First Moscow State Medical University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention group","EXPERIMENTAL","Patients of the experimental group will receive standart therapy HFpEF and rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08\u002F31\u002F2010) at a dose of 200 mg 3 times a day for 7 days.",[13,14],"Drug: Rifaximin","Other: Standard HFpEF treatment",{"label":16,"type":17,"description":18,"interventionNames":19},"control group","ACTIVE_COMPARATOR","Patients of the control group will receive standart therapy HFpEF Without Rifaximin",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Rifaximin","Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08\u002F31\u002F2010) in standard doses of 200 mg 3 times a day for 7 days",[9],[27],"Alfa Normix®",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Standard HFpEF treatment","diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor",[16,9],null,[34],{"name":35,"affiliation":36,"role":37},"Vladimir Ivashkin","I.M. Sechenov First Moscow State Medical University (Sechenov University)","PRINCIPAL_INVESTIGATOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":32,"email":43},"Konstantin Ivashkin","CONTACT","+7 926 213 58 33","ivashkin_k_v@staff.sechenov.ru",{"name":45,"role":41,"phone":46,"phoneExt":32,"email":47},"Elena Bueverova","+7 916 526 6245","bueverova_e_l@staff.sechenov.ru",[49],{"facility":50,"status":51,"city":50,"state":32,"zip":32,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Moscow","RECRUITING","Russia","RU",{"type":55,"coordinates":56},"Point",[57,58],37.61781,55.75204,{"lat":58,"lon":57},[61],{"name":45,"role":41,"phone":32,"phoneExt":32,"email":32},{"type":63,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100566200","rifaximin-and-cardiac-function-in-patients-with-heart-failure-with-preserved-ejection-fraction-100566200",false,"NCT06652087","Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction","The Effect of Correction of Bacterial Overgrowth Syndrome in the Small Intestine on Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction","SIBO-HFpEF","Inclusion Criteria:\n\n1. availability of written informed consent of the patient to participate in the study\n2. adult aged ≥18≤80 years' old\n3. body mass index ≥25 kg\u002Fm2\n4. diagnosed with HFpEF: 1) symptoms and\u002For signs of heart failure; 2) left ventricular ejection fraction ≥50%; 3) increased levels of natriuretic peptides (NTproBNP≥125 pg\u002FmL); 4) at least one additional criterion: relevant structural heart disease (hypertrophy of the left ventricle (LVH) and\u002For enlargement of the left atrium (LAE) or diastolic dysfunction\n\nExclusion Criteria:\n\n1. refusal of the patient from further participation in the study\n2. identification of any disease or condition specified in the criteria for non-inclusion and the development of a severe pathological condition in which patient monitoring becomes poorly implemented and the presence of which may make it difficult to interpret the data (gastrointestinal bleeding, myocardial infarction, etc.)","ALL","18 Years","80 Years",{"count":76,"type":77},40,"ESTIMATED","INTERVENTIONAL",[80],"NA","Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) (SIBO-HFpEF). The aim of the study is to evaluate the efficacy and safety of rifaximin in patients with HFpEF and SIBO.",[83,84],"Bacterial Overgrowth Syndrome Small Bowel","Heart Failure with Preserved Ejection Fraction",[86,87,88,89,90,91],"Chronic heart failure with preserved ejection fraction","Diastolic dysfunction","Overweight","Obesity","The gut-heart axis","Small intestinal bacterial overgrowth syndrome","2024-10-21",{"date":94,"type":95},"2024-10-22","ACTUAL",{"date":97,"type":95},"2024-09-02",{"date":99,"type":77},"2027-09-30",{"name":5,"class":6},1]